| A patient with lung adenocarcinoma and RET fusion treated with vandetanib O Gautschi, T Zander, FA Keller, K Strobel, A Hirschmann, S Aebi, ... Journal of Thoracic Oncology 8 (5), e43-e44, 2013 | 113 | 2013 |
| Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials S Hofer, K Elandt, R Greil, AF Hottinger, U Huber, D Lemke, C Marosi, ... Acta oncologica 50 (5), 630-635, 2011 | 54 | 2011 |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and … M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ... The Lancet Haematology 7 (6), e456-e468, 2020 | 46 | 2020 |
| Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy E Zucca, S Rondeau, A Vanazzi, B Østenstad, UJM Mey, D Rauch, ... Blood 134 (4), 353-362, 2019 | 21 | 2019 |
| Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. Primary … E Kimby, G Martinelli, B Ostenstad, UJM Mey, D Rauch, BE Wahlin, F Hitz, ... Blood, The Journal of the American Society of Hematology 124 (21), 799-799, 2014 | 21 | 2014 |
| Promising activity of nelfinavir-Bortezomib-Dexamethasone in proteasome inhibitor–refractory multiple myeloma C Driessen, R Müller, U Novak, N Cantoni, D Betticher, N Mach, A Rüfer, ... Blood 132 (19), 2097-2100, 2018 | 19 | 2018 |
| BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients S Gilli, U Novak, BM Taleghani, GM Baerlocher, K Leibundgut, Y Banz, ... Annals of hematology 96 (3), 421-429, 2017 | 19 | 2017 |
| The HIV protease inhibitor nelfinavir in combination with bortezomib and dexamethasone (NVd) has excellent activity in patients with advanced, proteasome inhibitor-refractory … C Driessen, R Müller, U Novak, N Cantoni, D Betticher, N Mach, M Gregor, ... Blood, The Journal of the American Society of Hematology 128 (22), 487-487, 2016 | 17 | 2016 |
| Response to Pembrolizumab in a patient with relapsing Thymoma T Zander, S Aebi, AC Rast, A Zander, R Winterhalder, C Brand, J Diebold, ... Journal of Thoracic Oncology 11 (12), e147-e149, 2016 | 15 | 2016 |
| Endocrinologic side effects of oncologic treatment with anti-CTLA-4-antibodies S Fischli, S Allelein, T Zander, C Henzen Deutsche medizinische Wochenschrift (1946) 139 (19), 996-1000, 2014 | 15 | 2014 |
| Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients C Kamber, S Zimmerli, F Suter-Riniker, BU Müller, BM Taleghani, ... Bone marrow transplantation 50 (4), 573-578, 2015 | 13 | 2015 |
| Rituximab plus lenalidomide versus rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. First analysis of survival endpoints of the randomized … E Kimby, S Rondeau, A Vanazzi, B Ostenstad, UJM Mey, D Rauch, ... Blood, The Journal of the American Society of Hematology 128 (22), 1099-1099, 2016 | 12 | 2016 |
| Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer MW Huellner, TP Hennedige, R Winterhalder, T Zander, SK Venkatesh, ... Cancer Imaging 12 (1), 212, 2012 | 12 | 2012 |
| Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland P Samaras, M Bargetzi, DC Betticher, MA Duchosal, D Heim, U Hess, ... Swiss medical weekly 145, 2015 | 11 | 2015 |
| The clinical value of echocardiography and acoustic cardiography to monitor patients undergoing anthracycline chemotherapy S Toggweiler, Y Odermatt, A Brauchlin, T Zander, A Müller, M Zuber, ... Clinical cardiology 36 (4), 201-206, 2013 | 10 | 2013 |
| Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for … O Gautschi, SI Rothschild, Q Li, K Matter-Walstra, A Zippelius, ... Clinical lung cancer 18 (3), 303-309, 2017 | 9 | 2017 |
| High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients I Prediletto, SA Farag, U Bacher, B Jeker, BM Taleghani, R Brégy, ... Bone marrow transplantation 54 (12), 1923-1925, 2019 | 8 | 2019 |
| Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma IG Amsler, B Jeker, B Mansouri Taleghani, U Bacher, D Betticher, T Egger, ... Leukemia & lymphoma 60 (2), 511-514, 2019 | 7 | 2019 |
| Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft U Gössi, B Jeker, B Mansouri Taleghani, U Bacher, U Novak, D Betticher, ... Hematological oncology 36 (2), 436-444, 2018 | 6 | 2018 |
| INDEPENDENT REVIEW OF CT RESPONSES IN THE TRIAL SAKK35/10 COMPARING RITUXIMAB WITH OR WITHOUT LENALIDOMIDE IN UNTREATED FL PATIENTS IN NEED OF THERAPY: 011 E Zucca, A Vanazzi, B Ostenstad, U Mey, D Rauch, B Wahlin, F Hitz, ... Hematological Oncology 33, 105-106, 2015 | 6 | 2015 |
PD Dr. med. Urban NovakMedical Oncology, Inselspital, Bern University HospitalBestätigte E-Mail-Adresse bei insel.ch
